Abstract. Around one sixth of breast cancer cases are classified as triple-negative breast cancer (TNBC), named after the absence of the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2); however, patients with TNBC suffer from poor clinical outcome and shortage of targeted therapy. Genistein, an estrogenic soy isoflavone, shows anticancer effects in TNBC cells such as inducing G2/M cell cycle arrest and apoptosis. However, the underlying mechanism of its anticancer effects is poorly understood and its elucidation can help the development of novel therapeutic strategies for TNBC. In this study, by combining isobaric tag-based TMT labeling with titanium dioxide-based phosphopeptide enrichment, we quantitated 5,445 phosphorylation sites on 2,008 phosphoproteins in the TNBC cell line MDA-MB-231, upon genistein treatment. Our analysis revealed 332 genistein-regulated phosphorylation sites on 226 proteins. Our data show that genistein can regulate several biological processes during the cell cycle, including DNA replication, cohesin complex cleavage, and kinetochore formation. Furthermore, genistein can also activate DNA damage response, including activation of ATR and BRCA1 complex. Overall, our study presents evidence at a phosphoproteomic level that genistein is able to inhibit TNBC cell growth by regulating the cell cycle and DNA damage response in a more complex manner. Our findings help elucidate the mechanisms through which genistein exerts its anticancer effects in TNBC cells.

Introduction

Breast cancer is the most common cancer and the leading cause of cancer-related death in women worldwide (1). It is not considered to be only one disease but a heterogeneous group of different diseases of distinct molecular subtypes. Breast cancer can be categorized into four subtypes, luminal A, luminal B, basal-like and HER2-positive (2,3). Three biomarkers, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) are often used for subtyping of breast cancer pathologically (2). Although the overall mortality rate for breast cancer patients has declined in developed countries, the patients diagnosed of basal-like subtype have a poorer short-term prognosis than those diagnosed with other breast cancer subtypes. The majority of basal-like breast cancer cases are also referred to as 'triple-negative' because they are characterized as the lack of the expression of these three biomarkers. Currently, no targeted therapies are available for these tumors. Thus, there is great unmet medical need for the development of novel molecular targeted therapeutic strategies.

Soy products have long been suggested to be useful in the prevention of cancer development (4,5). Epidemiological studies have shown the chemopreventive effect of soy intake for breast cancer (4,6). Especially, studies have shown that Asian women, who consume a diet high in soy products, have a lesser incidence of breast cancer and risk of breast cancer recurrence than the women in western counties (6).

Genistein, a phytoestrogen, is the major isoflavonoid contained in soybeans and is considered the active micronutrient
responsible for the chemopreventive effect of soy. It has a broad spectrum of anticancer properties in triple negative breast cancer (TNBC) cells. Genistein can inhibit cell growth (7), induce apoptosis (8) and G2/M phase arrest (9), and decrease cell invasiveness (10) in TNBC cells. Although a number of studies have been performed to dissect the molecular mechanisms of the effects of genistein on TNBC cells (8-13), they cannot comprehend its pleiotropic effects because of the limited throughput of traditional biochemical methods.

Multiplexed quantitation via isobaric labeling reagents [e.g., tandem mass tags (TMT) (14) and isobaric tags for relative and absolute quantitation (iTRAQ) (15)] combined with phosphopeptide enrichment has been employed to dissect complex signaling pathways using mass spectrometry. Nirujići et al combined an 8-plex TMT labeling strategy with titanium dioxide-based phosphopeptide enrichment to examine the changes of the phosphoproteome in the brains of rats after the exposure to VX, a nerve agent (16). Roitinger and colleagues combined a 4-plex iTRAQ labeling strategy with a phosphopeptide enrichment pipeline (immobilized metal affinity chromatography coupled with metal oxide affinity chromatography) to characterize the DNA damage response signaling pathway in Arabidopsis thaliana (17). Herein, we employed a TMT-based quantitative phosphoproteomic approach to identify genistein-regulated changes of phosphorylation in TNBC cell line, MDA-MB-231 after the short-term treatment. All together, we identified 5,445 phosphorylation sites on 2,008 phosphoproteins out of 3,452 proteins identified. The TMT-based quantitation revealed 332 genistein-regulated phosphorylation events. Bioinformatics analysis revealed that genistein can modulate phosphorylation on proteins involved in regulation of the cell cycle and DNA damage response. They include critical components of DNA replication fork, cohesin complex, kinetochores, and the BRCA1 complex. Manual literature curation provides evidence that genistein-induced changes on these proteins could contribute to its anticancer effects. Overall, our data set provides a valuable resource for further investigation on the anticancer molecular mechanism of genistein in TNBC cells.

Materials and methods

Cell line and reagents. The breast cancer cell line MDA-MB-231 was maintained in DMEM supplemented with FBS, L-glutamine, penicillin, streptomycin at 37°C in 5% CO₂. Genistein was purchased from Sigma-Aldrich (St. Louis, MO, USA). Titanspheres (TiO₂, 5 µm beads) were from GL Sciences Inc. (Torrance, CA, USA). L-1-Tosylamide-2-phenylethyl chloromethyl ketone (TPCK) treated trypsin was from Worthington Biochemical Corp. (Lakewood, NJ, USA). All other reagents used in this study were from Fisher Scientific (Pittsburgh, PA, USA).

Cell lysis, protein digestion and TMT labeling. MDA-MB-231 cells were plated at 3x10⁶ cells per 150-mm plate overnight. Three populations of cells were subjected to different treatments with 40 µM genistein for 0, 3 or 24 h, respectively. The treatments were carried out in biological duplicates. After treatment, cells were washed with PBS, collected and lysed in lysis buffer (4% SDS, 50 mM triethylammonium bicarbonate (TEABC), 10 mM sodium fluoride, 1 mM sodium orthovanadate and 1 mM β-glycerophosphate, 2.5 mM sodium pyrophosphate) by sonication. After centrifugation at 16,000 x g at 15°C for 20 min, the supernatant was collected and the protein concentration was determined using bicinchoninic acid (BCA) assay (Pierce, Waltham, MA, USA). An equal amount of protein (400 µg) from each condition was reduced by DTT at a final concentration of 5 mM at 60°C for 20 min and alkylated using 10 mM iodoacetamide for 10 min at room temperature (RT) in the dark.

The samples were then subjected to the filter-assisted sample preparation protocol (18) with minor modifications. Briefly, after reduction and alkylation, the protein was mixed with UA solution (8 M urea in 50 mM TEABC, pH 8.0) to dilute the concentration of SDS to 0.1% and transferred to an Amicon Ultra centrifugal filter unit (30 kDa cut-off, Millipore). The unit was centrifuged at 14,000 x g at 20°C for 15 min. The concentrate was diluted with 400 µl of UA solution and then subjected to centrifugation. This step was repeated once. The resulting concentrate was then diluted with 400 µl of 50 mM TEABC, pH 8.0 followed by centrifugation. This step was repeated once. The concentrate was transferred to a fresh tube and subjected to tryptic digestion overnight. The resulting peptides were dried completely in a vacuum concentrator and kept at -80°C.

Tandem mass tag (TMT) labeling was carried out according to the manufacturer instructions. Briefly, tryptic peptides from each sample was reconstituted in 100 µl of 50 mM TEABC buffer and mixed with the TMT reagent reconstituted in 41 µl of anhydrous acetonitrile (ACN), incubated at RT for 1 h. All the labeled peptides from each sample were equally mixed, dried completely in a vacuum concentrator and kept at -80°C.

Fractionation of peptides by basic reversed-phase liquid chromatography (bRPLC). TMT-labeled peptide mixture were resuspended in 1 ml of 10 mM TEABC, pH 8.0 and loaded on a XBridge BEH C18 column, 130Å, 5 µm, 4.6 mm X 250 mm (Waters, Milford, MA, USA), and fractionated on an Agilent 1100 Series HPLC system by basic reversed-phase chromatography at a flow rate of 400 µl/min. Mobile phase consisted of 10 mM TEABC, pH 8.0 (buffer A) and 10 mM TEAB, 90% acetonitrile, pH 8.0 (buffer B). After loading 1 ml of sample (2.4 mg of protein) onto the column, the peptides were separated using the following gradient: 2 min isocratic hold at 0% B, 0 to 15% solvent B in 8 min; 15 to 28.5% solvent B in 33 min; 28.5 to 34% solvent B in 5.5 min; 34 to 60% solvent B in 13 min, for a total gradient time of 64.5 min. Using 96X 1 ml well plates (Fisher, #7701-5200), fractions were collected every 0.6 min for a total of 96 fractions through the elution profile of the separation. Collection (5%) from each well were merged into 6 fractions and dried by vacuum centrifugation for the LC-MS/MS analysis of the proteomic changes in cells. The rest collected from each well was merged into 12 fractions and dried by vacuum centrifugation for TiO₂-based phosphopeptide enrichment.

Phosphopeptide enrichment strategy. The 12 fractions of TMT-labeled peptides were subjected to TiO₂-based phosphopeptide enrichment as described by Larsen et al (19) with minor modification. Briefly, TiO₂ beads were pretreated by
incubation with 2,5-dihydroxybenzoic acid (DHB) solution (80% v/v ACN, 3% v/v TFA, 5% w/v DHB) for 20 min at room temperature. Each fraction was resuspended in DHB solution and incubated with pretreated TiO$_2$ beads (Peptides: TiO$_2$=1:1). Phosphopeptide-bound TiO$_2$ beads were washed twice with 400 µl of washing solution (80% v/v ACN, 3% v/v TFA). Peptides were eluted three times with 20 µl of 4% v/v ammonia into 20 µl of 20% v/v TFA and dried completely by vacuum centrifugation. The dried peptides were resuspended in 50 µl 0.15% TFA, and desalted using C18 Stage Tips (20).

**Liquid chromatography tandem mass spectrometry.** LC-MS/MS analysis of peptides and phosphopeptides was carried out using a reversed phase liquid chromatography system interfaced with an LTQ-Orbitrap Velos mass spectrometer. The mass spectrometer was operated in the ‘high-high’ mode, where mass spectra of both precursor and product ions were acquired in the high resolution Orbitrap analyzer (Thermo Scientific). The peptides were loaded onto an analytical column (10 cm x 75 µm, Magic C18 AQ 5 µm, 120 Å) by 0.1% v/v formic acid and eluted using an ACN gradient (0-60% v/v) containing 0.1% v/v formic acid. The settings were: i) Precursor scans (FTMS) from 350-1,800 m/z at 30,000 resolution; and ii) MS2 scan (FTMS) of HCD fragmentation of the 10 most intense ions (isolation width: 1.20 m/z; normalized collision energy: 40.0; activation time=0.1 msec; FT first mass value: 110.00 (fixed)) at 15,000 resolution.

**Mass spectrometry data analysis.** The tandem mass spectra were searched using Andromeda algorithm (21) against a human UniProt database (released in February, 2014) through the MaxQuant platform (version 1.4.1.2) (22,23). The search parameters included: 6plex TMT; a maximum of two missed cleavages; fixed modification: carbamidomethylation of cysteine; variable modification: protein N-term acetylation, oxidation of methionine, and phosphorylation of serine, threonine and tyrosine. The first search and main search for peptide tolerance were set to 20 ppm and 4.5 ppm, respectively. The FTMS MS/MS tolerance was set to 50 ppm. The maximum number of modifications per peptide was set to 5 and the maximum charge was set at 7. The reward type of the target-decoy analysis was chosen. The peptide-spectrum match (PSM) false discovery rate (FDR), protein FDR and the site decoy fraction were set to 0.01. The minimal peptide length was set to 7. The minimal scores for unmodified and modified peptides were 0 and 40, respectively. The minimal delta score for unmodified and modified peptides were 0 and 17, respectively. The minimum of unique and razor peptides for identification was set to 1. The reporter ion intensities for each PSM with PIF (precursor ion fraction) >0.75 were calculated using MaxQuant. The quantitation of identified proteins was determined by normalized reporter ion intensities using at least 1 razor/unique non-phosphopeptide. The quantitation of each identified phosphosites was determined by normalized reporter ion intensities using the least modified peptide and normalized. The probability of phosphorylation for each Ser/Thr/Tyr site on each peptide was calculated using Andromeda (MaxQuant). The mass spectrometry proteomics data and the supplementary data have been deposited to the ProteomeXchange Consortium (24) via the PRIDE partner repository with the dataset identifier PXD002735 (http://www.ebi.ac.uk/pride/archive/projects/PXD002735/files).

**Bioinformatics analysis.** Molecular function and cellular localization of phosphoproteins were obtained from the PANTHER Classification System (25,26). Enrichment analysis of biological process GO term of phosphoproteins was performed using the DAVID functional annotation tool (27,28).

**Results**

**Mass spectrometric analysis of genistein-treated TNBC cells.** Previously, several studies have shown that genistein inhibits cell growth and induces apoptosis in a dose-dependent manner (8,11,12,29) during the treatment time ranging from 24 h to 6 days. However, the short-term effects of genistein on the signaling network in TNBC MDA-MB-231 cells during the first 24-h treatment, especially at 3-h time point, have not been investigated. By combining a 6-plex TMT labeling
strategy and a TiO$_2$-based phosphopeptide enrichment strategy coupling with high resolution Fourier transform mass spectrometry, we systematically measure the changes of the cellular phosphoproteome in biological duplicate experiments at two different time points, 3-h and 24-h treatments, as shown in Fig. 1.

Eighteen LC-MS/MS runs generated a total of 247,126 mass spectra. The mass spectra were searched against a Uniprot database (released in February, 2014) using Andromeda (21) through MaxQuant (Version 1.4.1.2) (23). Using a FDR cut-off of 1% at both peptide and protein levels, a target-decoy analysis generated 27,666 peptide-spectrum-matches, of which 14,462 were phosphopeptide-spectrum-matches. After excluding reverse and contaminating matches, we identified a total of 3,452 proteins and 12,813 peptides. Among these identified peptides, 4,562 were phosphopeptides that contained 5,445 phosphorylation sites (4,698 phosphoserine, 725 phosphothreonine, 22 phosphotyrosine sites). These phosphopeptides were mapped to 2,008 phosphoproteins. Fig. 2 shows the numbers of these phosphoproteins categorized by molecular function (A) or cellular component (B) based on the annotation by the PANTHER classification system.

Figure 2. Molecular function and cellular localization distribution of phosphoproteins identified in our study. The GO annotation describing the numbers of identified phosphoproteins with different molecular functions (A) and cellular locations (B) as obtained from the PANTHER.

Figure 3. Quantitative analysis of fold changes of proteins and phosphorylation in genistein-treated MDA-MB-231 cells. Density scatter plot of fold changes of the protein level (A and B) and phosphorylation level (C and D) in 3 h (A and C) and 24 h (B and D) genistein-treated MDA-MB-231 cells from biological duplicates. All the data are log10-transformed.
The quantitation of proteins and phosphosites was determined by the reporter ion intensities using the MaxQuant platform. The reporter ion intensities derived from mass spectra with precursor ion fraction (PIF) of >0.75 were considered for the quantitation. The changes of identified proteins were carried out using the quantitation of non-phosphopeptides, while changes in phosphosites were calculated using the least-modified phosphopeptides and then normalized to the changes of the corresponding protein, if possible. We were able to quantitate 2,087 proteins and 4,750 phosphosites (Fig. 3 and data not shown). Table I summarizes the statistics of the quantitative data on the fold-changes of proteins and phosphorylation in genistein-treated MDA-MB-231 cells. The narrow range of 95% confidence interval suggests that the majority of quantitated proteins remained unchanged during the course of genistein treatment in cells. Previously, TMT-based quantitative proteomics studies have chosen 1.5-fold change as a cut-off for significant changes (16,30). Thus, we also chose 1.5-fold cut-off for increased protein/phosphorylation level and a 0.67-fold cut-off for decreased protein/phosphorylation level. Only the changes of phosphorylation that showed consistency in both biological replicate experiments were considered for further analysis. By using this cut-off, 2,078 out of 2,087 proteins remained unchanged during the 24 h treatment of TNBC cells with genistein, while the expression level of only 8 proteins were modulated by genistein (Table II). We also identified 332 genistein-regulated phosphorylation sites in our analysis (Table III and data not shown). Fig. 4 shows the distribution of phospho-serine, -threonine and -tyrosine sites among identified phosphosites (A) and genistein-regulated phosphosites (B).

**Genistein regulates a number of biological processes during the cell cycle in TNBC cells.** To identify the biological processes regulated by genistein, we performed enrichment analysis on the regulated proteins and phosphosites. The analysis revealed that genistein regulates a number of biological processes during the cell cycle in TNBC cells.

### Table I. Statistical analysis of quantitative proteomics and phosphoproteomics data.

**A. Fold change of the protein level of in MDA-MB-231 cells after treatment with genistein**

| Experiment | Time point (h) | Median (log10 transformed) | Mean (log10 transformed) | Standard deviation (log10 transformed) | 95% Confidence interval |
|------------|---------------|----------------------------|--------------------------|----------------------------------------|-------------------------|
| #1         | 3             | 1.03                       | 0.00889                  | 0.0752                                 | 0.858-1.213             |
|            | 24            | 1.01                       | 0.00504                  | 0.0604                                 | 0.880-1.162             |
| #2         | 3             | 1.02                       | 0.00182                  | 0.0951                                 | 0.807-1.250             |
|            | 24            | 1.02                       | 0.00475                  | 0.0732                                 | 0.854-1.196             |

**B. Fold change of the phosphorylation level in MDA-MB-231 cells after treatment with genistein**

| Experiment | Time point (h) | Median (log10 transformed) | Mean (log10 transformed) | Standard deviation (log10 transformed) | 95% Confidence interval |
|------------|---------------|----------------------------|--------------------------|----------------------------------------|-------------------------|
| #1         | 3             | 0.99                       | 0.00011                  | 0.1301                                 | 0.741-1.350             |
|            | 24            | 0.98                       | -0.00636                 | 0.0941                                 | 0.793-1.224             |
| #2         | 3             | 0.99                       | -0.00048                 | 0.1270                                 | 0.746-1.338             |
|            | 24            | 0.98                       | -0.00332                 | 0.0889                                 | 0.809-1.218             |

### Table II. The genistein-regulated proteins in MDA-MB-231 cells.

| Gene symbol | Protein Accession no. | 3 h | 24 h |
|------------|-----------------------|-----|------|
| **CCNB1** | G2/mitotic-specific cyclin-B1 | Q9NRN7 | 2.2 | 1.1  |
| **CSTB**  | Cystatin-B            | P04080 | 2.6 | 2.0  |
| **EEF1B2**| Elongation factor 1-β | P24534 | 1.7 | 1.1  |
| **PRC1**  | Protein regulator of cytokinesis 1 | O43663 | 1.6 | 1.0  |
| **TK1**   | Thymidine kinase, cytosolic | P04183 | 1.7 | 1.1  |
| **TPX2**  | Targeting protein for Xklp2 | Q9ULW0 | 1.6 | 1.1  |
| **HIST1H1C** | Histone H1.2 | P16403 | 0.57 | 0.87 |
| **TNKS1BPI** | 182 kDa tankyrase-1-binding protein | Q9C0C2 | 0.57 | 0.63 |
### Table III. A partial list of genistein-regulated phosphoproteins involved in regulation of the cell cycle in MDA-MB-231 cells.

| Gene symbol | Protein description | Uniprot ID | Phosphosite | Identified peptides | Fold change |
|-------------|---------------------|------------|-------------|---------------------|-------------|
| AKAP12      | A-kinase anchor protein 12 | Q02952     | S612        | EGVTPWApSFK         | 0.61 0.91   |
| AKAP9       | A-kinase anchor protein 9  | Q99996     | S45         | AQSDDGQPSKK         | 1.70 0.98   |
| ANLN        | Actin-binding protein anillin | Q9NQW6    | S72         | RCpSDNTEVEVSLENK    | 0.56 0.91   |
| ARHGAP19    | Rho GTPase-activating protein 19 | Q14CB8 | S422       | pSFSGLIK           | 1.72 1.05   |
| BRCA1       | Breast cancer type 1 susceptibility protein | P38398     | S753        | DLMQPSPGER         | 1.99 1.24   |
| C6orf106    | Uncharacterized protein C6orf106 | Q9H6K1    | S215        | NYPpSQEELIK        | 2.16 1.48   |
| CCNY        | Cyclin-Y-like protein 1; | Q8ND76; S73; S95 |          | ASTIFLSKpSQTDFVR    | 1.56 1.20   |
| CCNYL1      | Cyclin-Y              | Q8N7R7     |            |                     |             |
| CDC20       | Cell division cycle protein 20 homolog | Q12834    | T106        | ENQPSaQpTPTKK       | 2.12 1.14   |
| CDC6        | Cell division control protein 6 homolog | Q99741    | S94         | QLpSEVFETEDSK       | 1.88 0.86   |
| CDC3        | Cell division cycle-associated protein 3 | Q99618    | S94         | QLpSEVFETEDSK       | 1.88 0.86   |
| CDK1;       | Cyclin-dependent kinase 1; | P06493; T14; T14; T14 | IGEGpTpYGVVK | 2.83 1.21   |
| CDK2;       | Cyclin-dependent kinase 2; | P24941; Y15; Y15; Y15 | IGEGpTpYGVVK | 2.29 1.12   |
| CDK3        | Cyclin-dependent kinase 3 | Q00762     | Y19; Y19; Y19 | IGEGpTPYpVpYK   | 2.44 1.16   |
| CDK12       | Cyclin-dependent kinase 12 | Q9NYV4     | T893        | LYNSEESRPypTNK      | 1.59 1.93   |
| CDK16       | Cyclin-dependent kinase 16 | Q90556     | S153        | RVpSLOSEIGFK        | 1.48 1.57   |
| CENPF       | Centromere protein F   | Q45454     | S1747       | LQLQGLDLpSSR       | 0.54 1.06   |
| CENPFV      | Centromere protein V   | Q7Z7K6     | S47         | SApSQAGSK          | 1.93 0.87   |
| CLASP1      | CLIP-associating protein 1 isoform 5 | Q7Z460-4   | S687        | VVSQpSQpPGpSR       | 1.79 1.64   |
| CLASP2      | CLIP-associating protein 2 | O75122     | S455        | MYSQpSQpPGpSR       | 2.13 1.85   |
| CSNK1D      | Casein kinase 1 isoform δ | P48730     | S331        | GLPSTapSGR          | 0.71 0.57   |
| FAM83D      | Protein FAM83D        | Q9H4H8     | S462        | GTqSpSTEtpSPVSK     | 1.78 0.99   |
| FANCD2      | Fanconi anemia group D2 protein | Q9BXW9 | S717        | DGGPVTpSQESGQK      | 2.20 1.25   |
| GINS2       | DNA replication complex GINS protein PSF2 | Q9Y248     | S182        | TNLQPLESTQpSQDF     | 2.42 2.07   |
| GNL3L       | Guanine nucleotide-binding protein-like 3-like protein | Q9NVN8     | S465        | LLHpSPMK            | 1.70 1.20   |
| GSK3B       | Glycogen synthase kinase-3β | P49841     | S9          | TTPpSFAESCKPVQQPSA  | 1.86 1.66   |
| H2AFY       | Core histone macro-H2A.1; Histone H2A | O75367     | T129        | GKEA1IpTPPPAK       | 0.66 0.94   |
| HAUS6       | HAUS augmin-like complex subunit 6 | Q7Z4H7     | S552        | AVLSDpSPQLESGK      | 0.63 0.84   |
| HJURP       | Holliday junction recognition protein | Q8NCD3     | S412        | WLPpSPVK            | 1.60 0.88   |
| HP1BP3      | Heterochromatin protein 1-binding protein 3 isoform 3 | Q5SSJ5-3   | S3          | MApSpPRPK           | 0.47 0.89   |
| HP1BP3      | Heterochromatin protein 1-binding protein 3 isoform 3 | Q5SSJ5-3   | S4          | MApSpPRPK           | 0.47 0.89   |
| ID4         | DNA-binding protein inhibitor ID-4 | Q47928     | S5          | AVpSPVpRPSGR        | 1.82 1.17   |
| INCENP      | Inner centromere protein | Q9NQS7     | T219        | TSLQPTPAPAASPQGI    | 1.69 1.32   |
| ING5        | Inhibitor of growth protein 5 | Q8WYH8     | T147        | RtpSPSEEFPK         | 0.60 0.97   |
| KIF11       | Kinesin-like protein KIF11 | P52732     | T926        | LDIPGTPtpTPQR       | 1.68 0.98   |
| KIF1A       | Kinesin-like protein KIF1A | Q12756     | S1904       | DVtpSPLRPSR         | 1.98 0.97   |
| KIF20A      | Kinesin-like protein KIF20A | Q95235     | S825        | LQGQVpSAK           | 0.64 0.98   |
| Gene symbol | Protein | Uniprot ID | Phosphosite | Identified peptides | Fold change |
|-------------|---------|------------|-------------|---------------------|-------------|
| KIF20B      | Kinesin-like protein KIF20B | Q96Q89 | S1740 | FGDFLQHpSPSILQSK | 1.64 0.99 |
|             |         | T1644      |             | HPGCTpTPVTVK        | 1.56 0.99 |
| LMNB1       | Lamin-B1 | P20700     | S23 | AGGPTpTPLpSPTR    | 0.46 0.82 |
|             |         | T20        |             | AGGPTpTPLpSPTR      | 0.27 0.74 |
| LMNB2       | Lamin-B2 | Q03252     | S17 | AGGPApTPLpSPTR    | 0.51 0.77 |
|             |         | S404       |             | ATSSSSGpSLSATGR      | 0.63 0.88 |
|             |         | T14        |             | AGGPApTPLpSPTR      | 0.51 0.77 |
| MAP4        | Microtubule-associated protein 4 | P27816 | S636 | KCPsLpPAPDFVLK | 0.47 1.02 |
| MARCKS      | Myristoylated alanine-rich C-kinase substrate | P29966 | S145 | AEDGApTfpSSNTPK | 0.64 0.88 |
|             |         | S147       |             | AEDGATpSPSNETPK      | 0.52 0.79 |
|             |         | T143       |             | AEDGApTfpSSNTPK      | 0.55 0.93 |
| MCM3        | DNA replication licensing factor MCM3 | P25205 | S728 | TADpSEQETK | 5.6 2.04 |
| MCM6        | DNA replication licensing factor MCM6 | Q14566 | S762 | EIESEIdpSEEELINK | 9.62 2.19 |
| MDC1        | Mediator of DNA damage checkpoint protein 1 | Q14676 | S1086 | QDGpSEQEAPLQSLSE | 2.84 2.17 |
|             |         | S955       |             | GEPEpGpSQDQK        | 4.36 3.35 |
| MELK        | Maternal embryonic leucine zipper kinase | Q14680 | S356 | SNWPspSLEDVTASDK | 1.67 1.09 |
|             |         | S329       |             | VFPspSLER           | 1.72 1.03 |
| MIS18BP1    | Mis18-binding protein 1 | C9J2Q8 | S110 | ANypSPGK | 1.52 1.01 |
| NASP        | Nuclear autoantigenic sperm protein | P49321 | S421 | LPspSEQETK | 3.08 0.49 |
| NPM1        | Nucleophosmin | P06748 | S218 | DSKpSpTPR | 0.53 0.87 |
|             |         | S254       |             | MQApSIEK           | 0.40 0.81 |
|             |         | T219       |             | DSKpSpTPR           | 0.54 0.88 |
|             |         | T199       |             | SIRDpTPAK          | 0.63 0.81 |
| NUP214      | Nuclear pore complex protein Nup214 | P35658 | S678 | ITPPAAKPgpSPQAK | 1.52 1.08 |
| ORC2        | Origin recognition complex subunit 2 | Q13416 | T226 | VVSAPVGKEpTSPKR | 1.67 1.04 |
| POLA2       | DNA polymerase α subunit B | Q14181 | S152 | pSPHQLpSPSFPSPA   | 1.78 1.07 |
|             |         | T127       |             | TPSQK               | 1.78 1.02 |
|             |         | S165       |             | AISpTPETPTLK        | 1.78 1.02 |
|             |         | S165       |             | LFQGpGpSPVK         | 2.06 1.02 |
| PTTG1;      | Securin; Securin-2 | O95997; | T127 | FFpSAP1GlpSPR | 1.95 1.24 |
| PTTG2       |         | Q9NZH5     |             | EDPpSAP1GlpSPR      | 1.95 1.24 |
| RANBP2      | E3 SUMO-protein ligase RanBP2 | P49792 | S955 | FEPSpSGlGlpSPR | 1.95 1.24 |
| RB1         | Retinoblastoma-associated protein | P06400 | S807 | IPGNIpSPLKpSPYK | 1.66 1.08 |
|             |         | S811       |             | IPGNIpSPLKpSPYK      | 1.66 1.08 |
|             |         | T821       |             | ISEGlpPTpTKpTPR      | 1.76 1.09 |
|             |         | T823       |             | ISEGlpPTpTKpTPR      | 1.80 1.08 |
|             |         | T826       |             | ISEGlpPTpTKpTPR      | 1.77 1.09 |
| RBM10       | RNA-binding protein 10 | P98175 | S50 | EYGpSEQK | 2.55 1.52 |
| RECQL5      | ATP-dependent DNA helicase Q5 | O94762 | S815 | YTGEpGAGGHpSPAP | 2.11 1.50 |
|             |         |            |             | PQTETECLR            | 2.11 1.50 |
| REXO4       | RNA exonuclease 4 | Q9GZR2 | S111 | KETpSPQVK | 0.61 0.91 |
| RFC1        | Replication factor C subunit 1 | P35251 | S29 | TKpSDEETLK | 9.99 11.91 |
| SMC1A       | Structural maintenance of chromosomes protein 1A | Q14683 | S957 | GTMDIDSEQEGSpSQG | 2.34 1.38 |
|             |         |            |             | EDSVSQGSR            | 2.34 1.38 |
|             |         |            |             | EDSVSGSQR            | 2.34 1.38 |
|             |         |            |             | MEEpSpSGpSQGR        | 1.81 1.16 |
|             |         |            |             | MEEpSpSQpSQGR        | 3.13 1.78 |
processes regulated by genistein in cells, genistein-regulated phosphoproteins identified in our study were analyzed in the DAVID bioinformatics resources (27,28) using the biological process ontology terms. The analysis revealed that proteins involved in the cell cycle, mitosis, DNA replication and cell division were significantly enriched in genistein-regulated phosphoproteins (Table III and data not shown). Although it has been shown that genistein can induce G2/M cell cycle arrest and decrease the expression of CDK1 in MDA-MB-231 cells after 48 h of treatment (11), the results here indicated that genistein regulates various phases during the cell cycle. To understand the effects of genistein on regulation of the cell cycle, manual literature curation was performed to find the roles of the phosphorylation of these proteins during the progress of the cell cycle. Fig. 5A shows that three critical CDKs during the progress of the cell cycle were regulated by genistein, while Fig. 5B demonstrates that 3 h after the treatment, genistein increased the amount of the phosphopeptide ‘IGEGpTpYGVVYK’, which is shared among CDK1, CDK2, and CDK3. Fig. 5C illustrates that 8 protein critical for DNA replication were regulated by genistein in MDA-MB-231 cells. The quantitative analysis revealed that the phosphorylation levels of these proteins were increased after 3-h treatment with genistein and that the phosphorylation on MCM3, MCM5, and GINS2 even remains higher after 24-h treatment with genistein (Fig. 5D). Fig. 5E shows that genistein decreased phosphorylation level of ESCO2 and increased phosphorylation level of CDC20, PTTG1, SMC1A and SMC3 in cells, suggesting that genistein can inhibit cleavage of the cohesin complex during mitosis. Table III summarized the changes of phosphorylation of the proteins involved in the cell cycle progress. Although the effects of genistein-induced changes of phosphorylation of these proteins cannot be detailed here, for the first time, our data revealed that genistein regulates the cell cycle progression in a more comprehensive manner than previously reported (11).

Genistein activates the DNA damage response pathway in TNBC cells. The enrichment analysis by DAVID revealed that 23 genistein-regulated phosphoproteins are involved in response to DNA damage (data not shown). To understand phosphorylation-based regulation of DNA damage response pathway by genistein, we constructed a DNA damage response pathway by manual literature curation, as shown in Fig. 6A. Here, for the first time, we were able to demonstrate that ATR was hyper-phosphorylated at Thr1989, an autophosphorylation site crucial for ATR activation (31), by genistein at 3 h but not 24 h (Fig. 6B and C), consistent with previous report that genistein metabolite activates ATR in cells (32). In addition, our data also showed
that TOPBP1, which activates the ATR-ATRIP complex during stressed DNA replication (33,34), was hyperphosphorylated at Ser888 by genistein at 3 h but not 24 h (Fig. 6C). Thus, our data suggest that genistein may induce activation of ATR signaling in MDA-MB-231 cells in an acute manner. Noteworthy, in our analysis, BRCA1 and RAP80 (uIMC1) were hyperphosphorylated by genistein at 3 h, suggesting that genistein may activate the BRCA1-A and -B complexes via the ATR signaling pathway. Fig. 6C illustrates genistein-induced changes of 23 signaling molecules, which were quantitated by TMT-based quantitative phosphoproteomics, in ATM/ATR-mediated DNA damage response. Taken together, our analysis revealed the complexity of genistein-induced DNA damage response, which is more than reported previously by Vauzour and colleagues, especially during the acute treatment phase (32).

Discussion
Triple-negative breast cancer accounts for approximately 12-17% of breast cancer cases in women. Patients with triple-negative tumors have relatively poor clinical outlook, evidenced by lower 5-year survival rate and higher distant recurrence rate than other breast cancer patients. These patients cannot be treated with endocrine therapy or therapy targeting over-expressed receptors, due to no or less expression of ER/HER2/PR compared with other subtypes of breast cancer (35,36). There is an urgent need to develop a novel therapeutic strategy for these patients. Genistein, one of the major isoflavones in soy products, has been reported to inhibit proliferation of TNBC cells (8,11,12,29,37,38). A number of epidemiological studies reported a significant inverse association between soy
intake and risk of breast cancer incidence and recurrence (4,5). Thus, genistein can serve as a potential attractive therapeutic agent for TNBC.

Previously, a number of groups have attempted to understand the anti-proliferative effects of genistein in TNBC cells, especially MDA-MB-231 cells (8,10-13,29). Genistein may inhibit cell growth and induce apoptosis via multiple signaling pathways. Genistein can upregulate the expression of Bax and p21WAF1 and downregulate the expression of Bcl-2 and p53 (8). It can inhibit NF-κB activity via the Akt signaling pathway (13) or the Notch-1 pathway (29) or the MEK5/ERK5 pathway (12). Genistein also induces phosphorylation of ERK1/2 (11). However, we did not detect the reported changes of signaling molecules involved in these signaling pathways at a protein level. Especially, our analysis did not detect significant changes in the proteome induced by genistein in MDA-MB-231 cells, out of 2087 proteins, only the expression levels of 8 proteins were shown to be changed by genistein (Table II).
In contrast, for the first time, our data focusing on the acute genistein treatment phase showed that phosphorylation of a number of signaling molecules involved in the regulation of the cell cycle were regulated by genistein in TNBC cells.

In eukaryotes, the cell cycle can be divided into the five different phases: G0, G1, S, G2, and M phases (Fig. 5A). Two classes of proteins, cyclins and cyclin-dependent kinases (CDKs) determine the progress of the cell cycle. Among them, CDK1 and CDK2 are two critical kinases controlling the correct transition of the different phases in the cell cycle (Fig. 5A). Phosphorylation on the Thr14 and Tyr15 sites inhibits CDK1 kinase activity, preventing the G2/M transition (39). Genistein can induce G2/M phase arrest in MDA-MB-231 cells (9). Here, for the first time, we were able to detect the increased phosphorylation at the Thr14 and Tyr15 sites on CDK1 in MDA-MB-231 cells after 3 h exposure to genistein, although we cannot exclude the possibility that genistein could increase the conserved Thr14 and Tyr15 sites on CDK2 and CDK3 (Fig. 5B). The data suggest that genistein executes its effects on regulation of the cell cycle in a more acute and direct manner than what previously described (11).

Mitosis and cytokinesis occur during the M phase of the cell cycle. Our data demonstrated that genistein regulates phosphorylation of a number of proteins involved in mitosis and cytokinesis (Table III). The cohesin complex, consisting of SMC1A, SMC3, RAD21, and STAG2, can form a large protein ring to hold sister chromatids together before anaphase during mitosis (40). When anaphase starts, the anaphase promoting complex (APC) marks an inhibitory protein securin (PTTG1) with ubiquitination for degradation. The destruction of securin allows the activation of a protease called separase (ESPL1), which cleave the cohesin complex to allow the separation of sister chromatids. Phosphorylation of CDC20 by Bub1 mediates inhibition of APC by spindle checkpoint (41). ESCO2 is a cohesin acetyltransferase and required for the establishment of sister chromatid cohesion (42,43). As shown in Fig. 5E, our data indicated that genistein decreased phosphorylation level of ESCO2 and increased phosphorylation level of CDC20, PTTG1, SMC1A and SMC3 in cells, suggesting that genistein can inhibit cleavage of the cohesin complex during mitosis.

The kinetochore is the protein complex assembled at each centromere on sister chromatids that serves as the attachment site for spindle microtubules to pull sister chromatids apart during mitosis. CLASP1 and CLASP2 belong to a family of microtubule-associated proteins and are required at kinetochore for attached microtubules (44,45). Our data showed that phosphorylation at the Ser687 site on CLASP1 and at the Ser455 site on CLASP2 were elevated by genistein at 3-h and 24-h time point. CENPF is assembled onto kinetochores at late G2 phase and is involved in chromosome segregation during mitosis (46). Phosphorylation at the Ser1747 site on CENPF was found to be decreased by genistein at 3-h time point and to return to the normal at 24-h point. CENPV was identified from mitotic chromosome scaffolds by mass spectrometry and has been shown to be required for centromere organization, chromosome alignment and cytokinesis (47). Of note, genistein was found to increase phosphorylation at the Ser47 site on CENPV at 3-h and 24-h time points and to decrease phosphorylation at the Ser45 site on CENPV at 3-h, but not 24-h time point. The human Augmin complex (HAUS) plays a critical role in microtubule attachment to the kinetochore and central spindle formation (48). HAUS6, a subunit of the HAUS complex, was found to be hypophosphorylated by genistein at Ser552 at 3-h, but not 24-h time point. MIS18BP1, also called KNL-2, is required for CENP-A incorporation into chromatin. MIS18BP1 and CENP-A localize to centromeres throughout the cell cycle. The depletion of MIS18BP1 in cells causes defect of the kinetochore assembly and chromosome segregation (49). At 3-h time point, phosphorylation of MIS18BP1 at the Ser110 was elevated by genistein, but then decreased to the normal at 24-h. HJURP, a CENP-A chaperon, is also required for CENP-A localization to centromeres and incorporation of newly synthesized CENP-A into centromeres (50). It is sufficient to form a functional de novo kinetochore (51). Phosphorylation of HJURP was observed to be elevated by genistein at 3-h time point. Spindly (SPDL1), a mitotic checkpoint protein, is required for localization of dynein and dynactin to the mitotic kinetochore (52). Farnesylation plays a role in targeting Spindly to kinetochores. Here we reported the elevated phosphorylation of Spindly at Ser555 by genistein at 3-h time point. Our quantitative data on the phosphorylation of these proteins suggest that genistein may regulate the formation of the kinetochore by phosphorylation during mitosis, which has not been reported previously. Taken together, our data suggest that genistein may have a more direct effect on regulation of the cell cycle in a complex manner.

ATM (ataxia-telangiectasia mutated) and ATR (ataxia telangiectasia and Rad3-related protein) are two critical protein kinases to sense DNA lesions induced by DNA damage or DNA replication stress and then to elicit the cellular responses that include cell cycle arrest, DNA repair and apoptosis (53). Whereas ATM mostly responds to double-strand DNA breaks, ATR is activated by a broad spectrum of DNA damage, including persistent single-stranded DNA during stressed replication fork. Genistein can induce the phosphorylation of ATM/Chk2 in irradiated MDA-MB-231 cells (54). Our data showed that at 3 h, genistein can activate ATR by hyperphosphorylation at Thr1989, an autophosphorylation site crucial for ATR activation (31). TOPBP1, an interacting protein of DNA topoisomerase II β, binds to single-stranded DNA and activates the ATR-ATRIP complex during stressed DNA replication (33,34). Noteworthy, our data also showed that at 3 h, genistein can induce hyperphosphorylation of TOPBP1 at Ser888. Thus, our data suggest acute effects of genistein on ATR signaling in MDA-MB-231 cells.

*BRCA1* is a human tumor suppressor gene and its mutations lead to an increased risk for breast cancer. The *BRCA1* protein product plays critical roles in DNA repair, cell cycle checkpoint control, and maintenance of genomic stability (55,56). *BRCA1* executes its functions by forming at least three different protein complexes (57). The *BRCA1-A* complex, which contains the BRCA1-BARD1 heterodimer, UIMC1, BRCC3, BRE, FAM175A and BABAM1, recognizes and binds K63-linked polyubiquitin chains present on histone H2A and H2AX at DNA damage sites to promote DNA repair (58). The *BRCA1-B* complex consisting of the *BRCA1-BARD1* heterodimer, BACH1 and TOPBP1, binds DNA lesions during S phase at DNA damage sites and is required for progression through S phase (59). The *BRCA1-C* complex,
which also contains BRCA1-BARD1 heterodimer, RBPs8, and the MRN complex (MRE11A/RAD50/NBS1), binds to the double-stranded DNA breaks during S and G2 phase of the cell cycle and is required for DNA damage-induced Chk1 phosphorylation and the G2/M transition checkpoint (59,60). In our analysis, BRCA1 were hyperphosphorylated at Ser753 and Ser1524 by genistein at 3-h. While phosphorylation at Ser1524 is required for ATM-mediated S phase checkpoint and response to double-stranded DNA breaks (61,62), the role of phosphorylation at Ser753 remains unknown. Moreover, BRCA1-A complex subunit RAP80 (uIMC1), and TOPBP1, a component of the BRCA1 B complex, were also hyperphosphorylated by genistein at 3-h. Phosphorylation at Ser101 of RAP80 (uIMC1) is critical to target the BRCA1-A complex to specific ubiquitin structure at DNA damage sites (63,64). Thus, our data suggest that genistein may activate the BRCA1-A and -B complexes via the ATR signaling pathway. Taken together, we concluded that genistein may affect more acutely the active DNA damage response pathway in a complex manner.

The difference of our data from previous reports may be due to the difference of the time points chosen in each of the studies. We aimed to identify the early signaling events (i.e. 3-h) in cells after the treatment with genistein, while previous reports were focused on the long-term effects of genistein on signaling pathways (>24 h). Our approach allows us to demonstrate that genistein may induce G2/M cell cycle arrest and apoptosis by regulating the cell cycle and DNA damage response more acutely and directly than indicated by previous reports. Notably, our data also revealed that genistein can induce hyperphosphorylation of components of the MCM complex, which could lead to inhibition of DNA replication (65). Thus, genistein may induce G2/M cell cycle arrest via stressed DNA replication.

While we describe the phosphoprotein changes in the core components in the cell cycle and the DNA damage response signaling pathways, it is important to keep in mind that these protein modifications are not independent of the other components of these pathways. In fact, these core components interact with many other signaling molecules to mediate the biological effects of genistein in cells. Overall, our studies revealed the complexity of the genistein effects on regulation of the cell cycle and opened promising avenues for future investigation into question regarding early effects in TNBC cells following treatment with genistein.

Acknowledgements

This study was supported by the Fundamental Research Funds for the Cancer Hospital, Chinese Academy of Medical Sciences (Y.F., no. JK2014B10), National Basic Research Program of China (973 Program, Y.J., no. 2015CB553902), the Fundamental Research Funds for the Central Universities (Z.H., no. 33320140103), the National Natural Science Foundation of China (J.W., General Program: 81372829), and Beijing Municipal Natural Science Foundation (J.W., no. 7142140).

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
2. Reis-Filho JS and Pusztai L: Gene expression profiling in breast cancer: Classification, prognostication, and prediction. Lancet 378: 1812-1823, 2011.
3. Perou CM and Børresen-Dale AL: Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol 3: a003293, 2011.
4. Adlercreutz CH, Goldin BR, Gorbach SL, Höckerstedt KA, Watanabe S, Häimäläinen EK, Markkula MH, Mäkelä T, Wahälä KT and Adlercreutz T: Soybean phytoestrogen intake and cancer risk. J Nutr 125 (Suppl): S757-S770, 1995.
5. Messina MJ, Persky V, Setchell KD and Burnes S: Soy intake and cancer risk: A review of the in vitro and in vivo data. Nutr Cancer 21: 113-131, 1994.
6. Nechoita SJ, Caan BJ, Chen WY, Lu W, Chen Z, Kwan ML, Flatt SW, Zheng Y, Zheng W, Pierce JP, et al: Soy food intake after diagnosis of breast cancer and survival: An in-depth analysis of combined evidence from cohort studies of US and Chinese women. Am J Clin Nutr 96: 123-132, 2012.
7. Fioravanti L, Cappelletti V, Miodini P, Ronchi E, Brivio M and Di Fronzo G: Genistein in the control of breast cancer cell growth: Insights into the mechanism of action in vitro. Cancer Lett 130: 143-152, 1998.
8. Li Y, Upadhyay S, Bhuiyan M and Sarkar FH: Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene 18: 3166-3172, 1999.
9. Cappelletti V, Fioravanti L, Miodini P and Di Fronzo G: Genistein blocks breast cancer cells in the G2/M phase of the cell cycle. J Cell Biochem 79: 594-600, 2000.
10. Horia E and Watkins BA: Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells. Carcinogenesis 28: 809-815, 2007.
11. Li Z, Li J, Mo B, Hu C, Liu H, Qi H, Wang X and Xu J: Genistein induces G2/M cell cycle arrest via stable activation of ERK1/2 pathway in MDA-MB-231 breast cancer cells. Cell Biol Toxicol 24: 401-409, 2008.
12. Li Z, Li J, Mo B, Hu C, Liu H, Qi H, Wang X and Xu J: Genistein induces cell apoptosis in MDA-MB-231 breast cancer cells via the mitogen-activated protein kinase pathway. Toxicol In Vitro 22: 1749-1753, 2008.
13. Gong L, Li Y, Nededjkovic-Kurepa A and Sarkar FH: Inactivation of NF-kappaB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene 22: 4702-4709, 2003.
14. Thompson A, Schäfer J, Kuhn K, Kienle S, Schwarz J, Schmidt G, Neumann T, Johnstone R, Mohammed AK and Hämmerling G: Tandem mass tags: A novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal Chem 75: 1895-1904, 2003.
15. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khaivinovski N, Pillai S, Dey S, Daniels S, et al: Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tag reagents. Mol Cell Proteomics 3: 1154-1169, 2004.
16. Nirujoyi RS, Wright JD Jr, Manda SS, Zhong J, Na CH, Meyerhoff J, Benton B, Jabbour R, Willis K, Kim MS, et al: Phosphoproteomic analysis reveals compensatory effects in the pim1/pim2 cortex of Vx nerve agent exposed rats. Proteomics 15: 487-499, 2015.
